“In terms of the individual patient, your best chance is your first chance. The time you lose you on your first regimen, it’s an important milestone. When I treat a child I don’t want to prolong life by 5 or 10 years. I want to get that child to 60 years of age, I want him to finish school, go to university, be a parent. So the only way you can do it is by sequencing your regimens and treatments the right way. So you’re hoping that 20 or 25 years from now there will be other strategies to take that person further on in life. So it’s a huge challenge, and maybe a bit of a dream target. But it may become true, I believe it will.”

- Dr. Avy Violari,
Deputy Executive Director

Dr. Avy Violari, MD, FCPaed (SA)
Deputy Executive Director
Director: Paediatric Clinical Trials

Dr. Violari is a paediatrician who is the head of PHRU's paediatric division. She was the lead investigator of the CHER trial at the PHRU. CHER is a landmark study that resulted in a major change to World Health Organisation (WHO) paediatric antiretroviral therapy guidelines. Dr. Avy Violari led one of the largest and most successful prevention of mother-to-child transmission of HIV (PMTCT) programmes in Africa. She has extensive clinical trials experience in paediatric and PMTCT research with a special interest in HIV/AIDS in children, especially infants with early infection. Dr. Violari has been involved in 24 HIV/AIDS trials, acting as Principal Investigator for 6 of them. Currently, she is the Principal Investigator of the PROMISE trial at the PHRU, which is one of the largest and most ambitious PMTCT trials ever undertaken.